One of the goals to be achieved in the Sustainable Development Goals ( SDGs ) is to ensure a healthy life and encourage prosperity for all people in all ages. One of the challenges in addressing the public health problem is with the One Health approach. One Health concept  emphasizes that human health associated with the environment and animal health (CDC 2016). One of factors triggering the increasing incidence of antibiotic resistance is unwise of using antibiotics in humans and animals. The assosiation of antimicrobial resistance in humans is also related to  the incidence of antibiotic resistance in animals, especially to livestock due to the use of Antibiotic Growth Promoters (AGP) with a sub-therapeutic level. This research aims to describe the result of drug content assays; product A, B, and C on drug registration dossier from Company X and its relation to  government regulation (Ministry of Agriculture)  in order to prevent the incidence of antibiotic resistance. This research uses descriptive analysis and laboratory assays of two drug samples using HPLC (High Performance Liquid Chromatography) and one drug sample using spectrofotometer at Pharmacy Laboratory, Pancasila University, in August - October 2015. Results obtained two samples do not fulfil  the standard; Product A (active ingredient: ciprofloxcacin) and Product B (active ingredient: enrofloxcacin)  each obtained at 33.76 g/kg  and  41,88 g/kg; while Product C (active ingredient: flumequine) met at 219.45 mg/mL. The distribution of drugs which are not according to standard is one important factor to the presence of antibiotic resistance. Therefore, the government role is important related to the regulations, supervision of drug imports, drug production, and distribution of animal drugs in Indonesia. The implementation of national strategy of antibiotic resistance should involve stakeholders (government, breeders, and drug companies).